Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01600482 · ClinicalTrials.gov registry record · NA

Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)

A NA study of Coronary Artery Disease and Cardiac Disease, sponsored by Vasorum.

Completed
Registry status
NA
Development phase
241
Enrollment target
5
Study locations

NCT01600482 is a NA study of Coronary Artery Disease and Cardiac Disease that has completed, run by Vasorum. The registered enrollment target is 241 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01600482, a NA study of Coronary Artery Disease and Cardiac Disease, has completed, sponsored by Vasorum.

COMPLETED
Registry status
NA
Development phase
241 participants
Enrollment target
5
Study locations

Study Summary

The objective of the CELT ACD® Vascular Closure Device study is to evaluate the safety and effectiveness of the CELT ACD® device to achieve hemostasis of the common femoral artery access site in patients on anticoagulation who are undergoing a percutaneous intervention (PCI) procedure using a 6F sheath.

Interventions

  • DEVICE CELT ACD

Study Locations (5)

New Jersey

  • Cooper University Hospital - Camden

New York

  • New York Presbyterian Hospital - New York

Neuss

  • Städtische Kliniken Neuss - Lukaskrankenhaus - GmbH - Preußenstr. 84,41464 Neuss

Other

  • Charite Campus Mitte - Berlin

Ireland

  • Galway University Hosptial - Galway

Trial Details

FieldValue
Enrollment Target 241 participants
Start Date 2012-05
Est. Completion 2016-02
Phase NA

Sponsor

Vasorum

1 total trials

What the Registry Record Tells You About NCT01600482

The ClinicalTrials.gov registry entry for NCT01600482 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (81% lower). The listed sponsor is Vasorum, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which CELT ACD is the first listed.

NCT01600482 reports 5 study locations spanning 5 distinct geographic areas - top geographies include New Jersey, New York, Neuss.

Frequently Asked Questions

What is clinical trial NCT01600482 about?

NCT01600482 is a clinical study titled "Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)". The objective of the CELT ACD® Vascular Closure Device study is to evaluate the safety and effectiveness of the CELT ACD® device to achieve hemostasis of the common femoral artery access site in patients on anticoagulation who are undergoing a percutaneous intervention (PCI) procedure using a 6F she...

What is the current status of trial NCT01600482?

This trial is currently completed. It is a NA study. The enrollment target is 241 participants. The study started on 2012-05. Estimated completion is 2016-02.

What conditions does trial NCT01600482 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Cardiac Disease.

What interventions are being tested in trial NCT01600482?

The interventions under investigation include: CELT ACD (DEVICE).

Who is sponsoring clinical trial NCT01600482?

This trial is sponsored by Vasorum, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01600482 being conducted?

This trial has 5 study locations across New Jersey, New York, Neuss, Ireland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.